Reported Earnings • Jun 10
Full year 2026 earnings: EPS and revenues exceed analyst expectations Full year 2026 results: EPS: ₹24.63 (up from ₹22.41 in FY 2025). Revenue: ₹16.3b (up 31% from FY 2025). Net income: ₹1.41b (up 9.9% from FY 2025). Profit margin: 8.6% (down from 10% in FY 2025). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 2.7%. Earnings per share (EPS) also surpassed analyst estimates by 1.1%. Revenue is forecast to grow 20% p.a. on average during the next 2 years, compared to a 17% growth forecast for the Life Sciences industry in India. Announcement • Jun 04
Innova Captab Limited, Annual General Meeting, Jun 29, 2026 Innova Captab Limited, Annual General Meeting, Jun 29, 2026, at 11:00 Indian Standard Time. Reported Earnings • May 08
Full year 2026 earnings released: EPS: ₹24.63 (vs ₹22.41 in FY 2025) Full year 2026 results: EPS: ₹24.63 (up from ₹22.41 in FY 2025). Revenue: ₹16.4b (up 32% from FY 2025). Net income: ₹1.41b (up 9.9% from FY 2025). Profit margin: 8.6% (down from 10% in FY 2025). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 19% p.a. on average during the next 2 years, compared to a 17% growth forecast for the Life Sciences industry in India. Announcement • May 04
Innova Captab Limited to Report Q4, 2026 Results on May 07, 2026 Innova Captab Limited announced that they will report Q4, 2026 results on May 07, 2026 Valuation Update With 7 Day Price Move • May 04
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to ₹846, the stock trades at a forward P/E ratio of 27x. Average forward P/E is 47x in the Life Sciences industry in India. Total loss to shareholders of 6.5% over the past year. Simply Wall St's valuation model estimates the intrinsic value at ₹510 per share. New Risk • Jan 27
New minor risk - Dividend sustainability The company has a short dividend paying track record. Less than a year of continuous dividend payments. Dividend yield: 0.6% This is considered a minor risk. For dividend focussed investors, companies that have not established a long-term track record of consistently maintaining or growing dividends are less attractive than those companies that have a long track record. Those that have a long track record have proven their underlying business is stable enough to consistently maintain or grow the dividend and that the company considers maintaining the dividend to be one of its priorities. For dividend paying companies, any reduction in the dividend can significantly impact the share price. This is currently the only risk that has been identified for the company. Reported Earnings • Jan 24
Third quarter 2026 earnings released: EPS: ₹7.37 (vs ₹5.97 in 3Q 2025) Third quarter 2026 results: EPS: ₹7.37 (up from ₹5.97 in 3Q 2025). Revenue: ₹4.50b (up 42% from 3Q 2025). Net income: ₹421.5m (up 23% from 3Q 2025). Profit margin: 9.4% (down from 11% in 3Q 2025). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Life Sciences industry in India. Announcement • Jan 23
Innova Captab Limited Declares an Interim Dividend for the Financial Year 2025-26 Innova Captab Limited, at its board meeting held on January 23, 2026, declared an Interim Dividend of INR 2/- per Equity Share of the Company (i.e. 20% of the face value of INR 10/- each of equity share) for the financial year 2025-26. The Record Date for determining the eligibility of shareholders for payment of Interim Dividend declared by the Board for the financial year 2025-26, has been fixed as 30th January, 2026. Announcement • Jan 16
Innova Captab Limited to Report Q3, 2026 Results on Jan 23, 2026 Innova Captab Limited announced that they will report Q3, 2026 results on Jan 23, 2026 Buy Or Sell Opportunity • Dec 09
Now 28% overvalued Over the last 90 days, the stock has fallen 14% to ₹752. The fair value is estimated to be ₹586, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has grown by 22%. Revenue is forecast to grow by 51% in 2 years. Earnings are forecast to grow by 74% in the next 2 years. Price Target Changed • Nov 13
Price target decreased by 25% to ₹809 Down from ₹1,076, the current price target is an average from 2 analysts. New target price is 11% above last closing price of ₹730. Stock is down 26% over the past year. The company is forecast to post earnings per share of ₹23.10 for next year compared to ₹22.41 last year. Reported Earnings • Nov 08
Second quarter 2026 earnings released: EPS: ₹5.18 (vs ₹6.12 in 2Q 2025) Second quarter 2026 results: EPS: ₹5.18 (down from ₹6.12 in 2Q 2025). Revenue: ₹3.85b (up 21% from 2Q 2025). Net income: ₹296.7m (down 15% from 2Q 2025). Profit margin: 7.7% (down from 11% in 2Q 2025). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 26% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Life Sciences industry in India. Announcement • Oct 31
Innova Captab Limited to Report Q2, 2026 Results on Nov 07, 2025 Innova Captab Limited announced that they will report Q2, 2026 results on Nov 07, 2025 Reported Earnings • Aug 08
First quarter 2026 earnings released: EPS: ₹5.42 (vs ₹5.15 in 1Q 2025) First quarter 2026 results: EPS: ₹5.42 (up from ₹5.15 in 1Q 2025). Revenue: ₹3.56b (up 21% from 1Q 2025). Net income: ₹310.2m (up 5.2% from 1Q 2025). Profit margin: 8.7% (down from 10.0% in 1Q 2025). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Life Sciences industry in India. Announcement • Jul 30
Innova Captab Limited to Report Q1, 2026 Results on Aug 07, 2025 Innova Captab Limited announced that they will report Q1, 2026 results on Aug 07, 2025 Reported Earnings • Jul 08
Full year 2025 earnings: EPS in line with expectations, revenues disappoint Full year 2025 results: EPS: ₹22.41 (up from ₹18.66 in FY 2024). Revenue: ₹12.4b (up 15% from FY 2024). Net income: ₹1.28b (up 36% from FY 2024). Profit margin: 10% (up from 8.7% in FY 2024). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 1.5%. Earnings per share (EPS) were mostly in line with analyst estimates. Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Life Sciences industry in India. Announcement • Jul 03
Innova Captab Limited, Annual General Meeting, Jul 31, 2025 Innova Captab Limited, Annual General Meeting, Jul 31, 2025, at 11:00 Indian Standard Time. Buy Or Sell Opportunity • Jun 12
Now 27% overvalued after recent price rise Over the last 90 days, the stock has risen 22% to ₹945. The fair value is estimated to be ₹744, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has grown by 23%. For the next 3 years, revenue is forecast to grow by 24% per annum. Earnings are also forecast to grow by 28% per annum over the same time period. Buy Or Sell Opportunity • May 23
Now 22% overvalued after recent price rise Over the last 90 days, the stock has risen 14% to ₹889. The fair value is estimated to be ₹726, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has grown by 23%. For the next 3 years, revenue is forecast to grow by 24% per annum. Earnings are also forecast to grow by 28% per annum over the same time period. Reported Earnings • May 20
Full year 2025 earnings: EPS in line with expectations, revenues disappoint Full year 2025 results: EPS: ₹22.41 (up from ₹18.66 in FY 2024). Revenue: ₹12.6b (up 16% from FY 2024). Net income: ₹1.28b (up 36% from FY 2024). Profit margin: 10% (up from 8.7% in FY 2024). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 1.5%. Earnings per share (EPS) were mostly in line with analyst estimates. Revenue is forecast to grow 29% p.a. on average during the next 2 years, compared to a 16% growth forecast for the Life Sciences industry in India. Announcement • May 13
Innova Captab Limited to Report Q4, 2025 Results on May 19, 2025 Innova Captab Limited announced that they will report Q4, 2025 results on May 19, 2025 Valuation Update With 7 Day Price Move • Mar 20
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to ₹894, the stock trades at a forward P/E ratio of 30x. Average forward P/E is 29x in the Life Sciences industry in India. Total returns to shareholders of 90% over the past year. Simply Wall St's valuation model estimates the intrinsic value at ₹590 per share. Buy Or Sell Opportunity • Mar 05
Now 23% overvalued Over the last 90 days, the stock has fallen 35% to ₹719. The fair value is estimated to be ₹587, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has grown by 25%. Revenue is forecast to grow by 83% in 2 years. Earnings are forecast to grow by 86% in the next 2 years. Valuation Update With 7 Day Price Move • Feb 12
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to ₹842, the stock trades at a forward P/E ratio of 28x. Average forward P/E is 32x in the Life Sciences industry in India. Total returns to shareholders of 55% over the past year. Simply Wall St's valuation model estimates the intrinsic value at ₹592 per share. Reported Earnings • Feb 06
Third quarter 2025 earnings released: EPS: ₹5.97 (vs ₹4.39 in 3Q 2024) Third quarter 2025 results: EPS: ₹5.97 (up from ₹4.39 in 3Q 2024). Revenue: ₹3.21b (up 6.1% from 3Q 2024). Net income: ₹342.0m (up 36% from 3Q 2024). Profit margin: 11% (up from 8.3% in 3Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 29% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Life Sciences industry in India. Announcement • Jan 29
Innova Captab Limited to Report Q3, 2025 Results on Feb 05, 2025 Innova Captab Limited announced that they will report Q3, 2025 results on Feb 05, 2025 Announcement • Jan 17
Innova Captab Limited Announces Commencement of Commercial Production At New Manufacturing Facility in Kathua, Jammu Innova Captab Limited announced the commencement of commercial production at its state-of-the-art manufacturing facility in Kathua, Jammu. The facility comprises four dedicated manufacturing blocks including General, Cephalosporin, Penicillin and Penum with a capability to manufacture a diverse range of products in oral solid dosages, dry powder injectables, dry syrup, BFS, large volume parenterals and respiratory respule products. With this expansion, the company, at a consolidated level, have total five manufacturing facilities with nine independent manufacturing blocks. The facility has been established with a total capital outlay of more than INR 4,500 million and with the start of commercial production, the Company is poised to benefit from the Central Government's 'New Central Sector Scheme', for Capital Interest Subvention of 6% per annum and GST-linked incentive of 300% of investment made in plant and machinery in 10 years. Valuation Update With 7 Day Price Move • Jan 13
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to ₹1,016, the stock trades at a forward P/E ratio of 34x. Average forward P/E is 38x in the Life Sciences industry in India. Total returns to shareholders of 98% over the past year. New Risk • Dec 26
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (28% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (7.6% average weekly change). Valuation Update With 7 Day Price Move • Nov 14
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to ₹992, the stock trades at a forward P/E ratio of 33x. Average forward P/E is 39x in the Life Sciences industry in India. Reported Earnings • Nov 08
Second quarter 2025 earnings released: EPS: ₹6.12 (vs ₹4.77 in 2Q 2024) Second quarter 2025 results: EPS: ₹6.12 (up from ₹4.77 in 2Q 2024). Revenue: ₹3.20b (up 13% from 2Q 2024). Net income: ₹350.0m (up 53% from 2Q 2024). Profit margin: 11% (up from 8.1% in 2Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Life Sciences industry in India. Announcement • Oct 31
Innova Captab Limited to Report Q2, 2025 Results on Nov 07, 2024 Innova Captab Limited announced that they will report Q2, 2025 results on Nov 07, 2024 Buy Or Sell Opportunity • Oct 14
Now 24% overvalued after recent price rise Over the last 90 days, the stock has risen 46% to ₹751. The fair value is estimated to be ₹605, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 22% over the last year. Earnings per share has grown by 38%. Revenue is forecast to grow by 74% in 2 years. Earnings are forecast to grow by 94% in the next 2 years. Buy Or Sell Opportunity • Sep 05
Now 22% overvalued after recent price rise Over the last 90 days, the stock has risen 47% to ₹736. The fair value is estimated to be ₹603, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 22% over the last year. Earnings per share has grown by 38%. Revenue is forecast to grow by 74% in 2 years. Earnings are forecast to grow by 94% in the next 2 years. Announcement • Aug 23
Innova Captab Limited, Annual General Meeting, Sep 18, 2024 Innova Captab Limited, Annual General Meeting, Sep 18, 2024, at 11:00 Indian Standard Time. Reported Earnings • Aug 10
First quarter 2025 earnings released: EPS: ₹5.15 (vs ₹3.67 in 1Q 2024) First quarter 2025 results: EPS: ₹5.15 (up from ₹3.67 in 1Q 2024). Revenue: ₹2.96b (up 27% from 1Q 2024). Net income: ₹294.8m (up 68% from 1Q 2024). Profit margin: 9.9% (up from 7.5% in 1Q 2024). The increase in margin was driven by higher revenue. Announcement • Aug 02
Innova Captab Limited to Report Q1, 2025 Results on Aug 09, 2024 Innova Captab Limited announced that they will report Q1, 2025 results on Aug 09, 2024 Valuation Update With 7 Day Price Move • Jul 24
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to ₹619, the stock trades at a trailing P/E ratio of 37.6x. Average trailing P/E is 38x in the Life Sciences industry in India. Reported Earnings • May 30
Full year 2024 earnings released: EPS: ₹18.66 (vs ₹14.16 in FY 2023) Full year 2024 results: EPS: ₹18.66 (up from ₹14.16 in FY 2023). Revenue: ₹10.9b (up 18% from FY 2023). Net income: ₹943.5m (up 39% from FY 2023). Profit margin: 8.6% (up from 7.3% in FY 2023). The increase in margin was driven by higher revenue. Announcement • May 22
Innova Captab Limited to Report Q4, 2024 Results on May 29, 2024 Innova Captab Limited announced that they will report Q4, 2024 results on May 29, 2024 Announcement • Mar 29
Innova Captab Limited Appoints Lokesh Bhasin as the Chief Financial Officer, Effective March 30, 2024 The board of directors of Innova Captab Limited at its meeting held on March 29, 2024, has appointed Mr. Lokesh Bhasin as the Chief Financial Officer and Key Managerial Personnel of the Company with effect from March 30, 2024. Terms of appointment as recommended by the Nomination & Remuneration Committee and Audit Committee and approved by the Board of Directors. Lokesh Bhasin is a Cost and Management Accountant from the Institute of Cost Accountants of India and holds Diploma in Information System Security Audit from the Institute of Cost Accountants of India. He has approximately 20 years of experience in the Corporate Finance & Accounts Sector. As a Deputy CFO with Innova Captab Ltd., he had performed an instrumental role in the entire IPO journey, from kick off meeting till listing of the shares. He has been actively involved in post listing reporting and compliances and plays an active role in other strategic initiatives. Before being associated with Innova Captab Ltd., he had served with Allied Nippon Pvt. Ltd., Exl Service India Pvt. Ltd., Escorts Limited & Air India Limited and at middle and senior management roles. In his previous positions, he had handled multiple functions such as merger & acquisitions, project implementation, ERP implementation and stabilisation, internal control & systems improvement, finance operations and controllership, banking and financial management, financial planning & analysis, budgeting & reporting, pricing & commercials, project management, HR and other major functions. Announcement • Mar 15
Innova Captab Limited Announces Resignation of Gaurav Srivastav as Chief Financial Officer, Effective March 29, 2024 Innova Captab Limited announced that Mr. Gaurav Srivastava, Chief Financial Officer has tendered his resignation with effect from the close of business hours of March 29, 2024. Reason for change: Due to personal reason. Announcement • Feb 06
Innova Captab Limited to Report Q3, 2024 Results on Feb 13, 2024 Innova Captab Limited announced that they will report Q3, 2024 results on Feb 13, 2024 Reported Earnings • Jan 19
Second quarter 2024 earnings released Second quarter 2024 results: EPS: ₹4.77. Net income: ₹229.1m (up ₹229.1m from 2Q 2023). Announcement • Jan 12
Innova Captab Limited to Report Q2, 2024 Results on Jan 18, 2024 Innova Captab Limited announced that they will report Q2, 2024 results on Jan 18, 2024 Board Change • Jan 01
High number of new and inexperienced directors There are 7 new directors who have joined the board in the last 3 years. The company's board is composed of: 7 new directors. 1 experienced director. No highly experienced directors. Whole-time Director Jayant Rao is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. 
